ResMed (NYSE: RMD) reported Q2 EPS of $1.88, $0.10 better than the analyst estimate of $1.78. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.15 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.